Prosensa named Most Innovative European Biotech SME

December 7, 2011: Dutch biopharmaceutical company Prosensa, which focuses on rare diseases with a high unmet medical need, has won EuropaBio’s Most Innovative European Biotech SME Award 2011, presented at a ceremony in Brussels, Belgium. The award comes with prize money of €10,000 and two years’ membership of EuropaBio.

The EuropaBio Award recognises the company’s pioneering role in helping patients and their families affected by rare, progressively debilitating diseases. Prosensa’s lead product, PRO051 (GSK2402968), is currently in Phase 3 trials in collaboration with GlaxoSmithKline (GSK), for the treatment of Duchenne muscular dystrophy (DMD). This is a rare, genetic, childhood disease that afflicts about 1 in 3,500 newborn boys. As early as the age of 2, boys begin to show signs of muscle weakness, they are often wheelchair bound before the age of 12 and few live to more than 30 years of age. There is currently no available therapy for DMD.

The technology used by Prosensa is a form of RNA modulation known as ‘exon skipping’, one of the most advanced techniques in modern genetics and molecular biology.

The selection process for the award was judged by G. Steven Burrill, Founder and CEO of Burrill & Company; Tom Saylor, CEO of Arecor and Chairman of EuropaBio’s SME Platform; Paul Ruebig, MEP and Chair of the SME Union; and Nathalie Moll, Secretary General of EuropaBio.